Skip to main content

Advertisement

SpringerLink
Log in

Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The appearance of tumor necrosis factor blockers changes the treatment goal of rheumatoid arthritis (RA) to include not only the inhibition of bone destruction, but also the induction of remission. We, herein, report two cases with RA that showed a prolonged remission after the discontinuation of etanercept. The two cases were 27 and 38 years of age, and their disease durations were 6 and 14 months, respectively. Their disease activity score 28 (DAS28) before treatment were 4.43 and 5.07, respectively. Case two was resistant to infliximab as determined by previous treatment with this therapy. Both cases showed a dramatic clinical response and discontinued etanercept in the 15th month and the 14th month after the start of treatment, respectively. No exacerbation of arthritis was evident after the discontinuation of etanercept as supported by the maintenance of DAS28 at less than 2.6. Moreover, after the discontinuation of etanercept, radiographic progression was not evident and decreased modified Sharp scores were observed for at least 1 year in both cases. These findings indicate that clinical and radiographic remission is possible in some patients with RA after the discontinuation of etanercept.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

References

  1. Drossaers-Bakker KW, de Buck M, van Zeben D, Zwinderman AH, Breedveld FC, Hazes JM (1999) Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 42:1854–1860

    Article  CAS  PubMed  Google Scholar 

  2. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907–916

    Article  CAS  PubMed  Google Scholar 

  3. van der Heijde D, Landewé R, Klareskog L, Rodríguez-Valverde V, Settas L, Pedersen R, Fatenejad S (2005) Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. Arthritis Rheum 52:49–60

    Article  PubMed  Google Scholar 

  4. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, Breedveld FC, Furst DE, Lipsky PE (2005) Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 52:1020–1030

    Article  CAS  PubMed  Google Scholar 

  5. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45

    Article  CAS  PubMed  Google Scholar 

  6. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BA (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52:3381–3390

    Article  CAS  PubMed  Google Scholar 

  7. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

    Article  CAS  PubMed  Google Scholar 

  8. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036–1038

    PubMed  Google Scholar 

  9. Nawata M, Saito K, Nakayamada S, Tanaka Y (2008) Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 18:460–464

    Article  CAS  PubMed  Google Scholar 

  10. Anolik JH, Ravikumar R, Barnard J, Owen T, Almudevar A, Milner EC, Miller CH, Dutcher PO, Hadley JA, Sanz I (2008) Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 180:688–692

    CAS  PubMed  Google Scholar 

  11. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Singh A, Pedersen RD, Koenig AS, Freundlich B (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 372:375–382

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Rheumatology, Clinical Research Center, National Hospital Organization Kyushu Medical Center, 1-8-1, Jigyouhama, Chuou-ku, Fukuoka, 8108563, Japan

    Tomoya Miyamura, Koshiro Sonomoto, Masataka Nakamura, Yoshiro Horai, Soichiro Takahama, Hitoshi Ando, Rumi Minami, Masahiro Yamamoto & Eiichi Suematsu

Authors
  1. Tomoya Miyamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Koshiro Sonomoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Masataka Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yoshiro Horai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Soichiro Takahama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hitoshi Ando
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rumi Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masahiro Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eiichi Suematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomoya Miyamura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miyamura, T., Sonomoto, K., Nakamura, M. et al. Discontinuation of etanercept in patients with rheumatoid arthritis who were in clinical remission. Clin Rheumatol 29, 87–90 (2010). https://doi.org/10.1007/s10067-009-1274-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-009-1274-0

Keywords

Search

Navigation